vitamin
defici
vad
one
common
nutrit
disord
world
estim
million
preschoolag
children
vad
least
million
show
clinic
vad
associ
increas
suscept
diseas
poor
respons
vaccin
increas
although
frank
vad
gener
consid
diseas
develop
world
margin
vad
problemat
even
develop
countri
popul
develop
world
reach
recommend
intak
plasma
liver
concentr
vitamin
lower
accept
prematur
infant
born
vad
despit
supplement
remain
biochem
defici
month
year
even
subclin
level
vad
link
increas
incid
sever
respiratori
vitamin
refer
group
fatsolubl
retinoid
includ
retinol
retin
retinyl
ester
anim
incap
de
novo
va
synthesi
therefor
dietari
va
obtain
diet
preform
va
anim
sourc
provitamin
carotenoid
betacaroten
plant
sourc
va
store
liver
need
releas
blood
stream
form
retinol
retinol
convert
bioactiv
form
retino
acid
ra
seri
enzym
includ
alcohol
dehydrogenas
retinaldehyd
dehydrogenas
va
ra
play
complex
role
regul
immun
system
vad
caus
reduc
alter
b
cell
respons
number
dysregul
product
type
alter
number
function
innat
immun
popul
includ
monocyt
nk
cell
dendrit
cell
role
va
ra
studi
context
immun
gastrointestin
tract
ra
play
import
role
regul
home
cell
promot
develop
regulatori
less
known
import
va
ra
lung
immun
function
given
known
epidemiolog
link
vad
respiratori
diseas
need
defin
role
va
ra
immun
respiratori
tract
human
respiratori
syncyti
viru
rsv
lead
caus
sever
acut
lower
respiratori
tract
diseas
infant
young
children
account
hospit
bronchiol
case
industri
global
estim
million
new
episod
hrsvassoci
diseas
children
year
age
result
sever
rsv
infect
link
develop
exacerb
recurr
wheez
predispos
factor
develop
otiti
despit
high
burden
treatment
rsv
infect
larg
support
vaccin
avail
prevent
reduc
diseas
bovin
respiratori
syncyti
viru
brsv
close
relat
human
rsv
primari
caus
sever
acut
lower
respiratori
tract
diseas
young
cattl
brsv
infect
calv
strikingli
similar
rsv
infect
human
similar
age
depend
innat
adapt
immun
respons
diseas
calf
model
use
understand
immun
respons
rsv
infect
physiolog
hostpathogen
interact
repres
tractabl
model
infant
immun
system
scalabl
model
use
test
novel
therapeut
intervent
strategi
nanoparticl
np
compos
biodegrad
polyanhydrid
shown
impress
versatil
immunogen
carrier
vaccin
recent
publish
develop
amphiphil
polyanhydrid
copolym
np
base
vaccin
ie
nanovaccin
compris
molar
composit
pcarboxyphenoxi
cpteg
pcarboxyphenoxi
hexan
cph
encapsul
fusion
f
attach
g
protein
brsv
brsvnp
brsvnp
vaccin
exhibit
sustain
releas
kinet
antigen
vitro
maintain
immunogen
antigen
payload
calv
receiv
singl
intranas
dose
brsvnp
vaccin
partial
protect
brsv
challeng
reduc
viral
load
lung
reduc
viru
shed
significantli
reduc
lung
patholog
compar
unvaccin
studi
protect
calv
associ
induct
virusspecif
iga
respons
nasal
secret
bronchoalveolar
lavag
fluid
virusspecif
cellular
immun
respons
lower
airway
peripher
given
high
burden
rsv
diseas
human
anim
develop
safe
effect
vaccin
critic
goal
importantli
howev
vaccin
half
equat
statu
host
immun
system
profound
impact
vaccin
efficaci
ultim
diseas
suscept
understand
factor
may
neg
affect
efficaci
vaccin
target
popul
also
vital
effect
immun
program
vad
endem
geograph
region
hit
hardest
also
highli
preval
prematur
infant
popul
known
increas
risk
epidemiolog
signific
correl
vad
increas
suscept
sever
rsv
howev
impact
defici
mucos
immun
function
explor
context
experiment
end
gener
calf
model
vad
assess
immun
respons
mucos
brsvnp
vaccin
subsequ
brsv
challeng
compar
respons
va
suffici
va
calv
report
va
brsvnp
immun
calv
protect
sever
rsvassoci
diseas
vad
calv
fail
respond
intranas
brsvnp
vaccin
develop
sever
brsvassoci
diseas
vad
brsvnp
immun
calv
mount
iga
respons
respiratori
tract
gener
virusspecif
cell
respons
lung
peripher
blood
gene
express
studi
demonstr
vad
calv
present
signific
abnorm
inflammatori
milieu
infect
lung
alter
immun
respons
impair
mucin
product
show
acut
respiratori
viral
infect
signific
neg
impact
circul
store
va
level
caus
even
vitaminreplet
calv
becom
va
defici
thu
result
show
va
statu
signific
impact
mucos
immun
system
resist
respiratori
viral
infect
determin
impact
vad
respons
mucos
vaccin
subsequ
rsv
challeng
first
establish
two
group
calv
differ
level
serum
liver
retinol
calv
born
low
va
level
colostrum
major
sourc
va
fatsolubl
therefor
calv
receiv
fraction
colostrum
replac
without
va
restor
place
va
vad
milk
replac
diet
serum
retinol
level
evalu
weekli
start
calv
differenti
diet
week
shown
fig
anim
low
serum
retinol
level
week
level
increas
va
group
reach
normal
serum
retinol
concentr
week
age
normal
rang
serum
retinol
juvenil
calv
day
plasma
va
level
tightli
regul
liver
therefor
optim
determin
va
statu
confirm
va
statu
two
treatment
group
liver
sampl
collect
time
necropsi
normal
rang
liver
retinol
juvenil
calv
seen
fig
calv
vad
treatment
group
normal
retinol
store
liver
time
necropsi
va
calv
normal
liver
store
previous
demonstr
intranas
brsvfg
nanovaccin
induc
partial
protect
brsv
challeng
young
colostrumreplet
determin
impact
vad
respons
intranas
vaccin
calv
va
treatment
group
calv
vad
treatment
group
immun
brsvnp
vaccin
prior
studi
inclus
solubl
antigen
cpteg
cph
npencapsul
protein
use
induc
rapid
immunogen
therefor
studi
also
sought
determin
whether
inclus
solubl
fg
protein
improv
efficaci
brsvnp
vaccin
calv
immun
intranas
singl
dose
mg
brsvfg
np
encapsul
mg
brsv
f
g
protein
coadminist
mg
solubl
f
g
protein
ml
steril
salin
six
va
calv
six
vad
calv
serv
unvaccin
control
four
week
immun
calv
challeng
via
aerosol
inocul
brsv
strain
calv
monitor
daili
clinic
sign
includ
bodi
temperatur
appetit
nasal
discharg
respiratori
effort
start
day
infect
anim
develop
fever
clinic
sign
lower
respiratori
tract
diseas
includ
cough
increas
respir
rate
increas
respiratori
effort
seen
fig
day
post
infect
clinic
diseas
significantli
reduc
vasbrsvnp
vaccin
calv
compar
vasunvaccin
anim
compar
vadbrsvnp
vaccin
calv
signific
differ
clinic
sign
observ
vasunvaccin
control
vadunvaccin
control
vadbrsvnp
vaccin
calv
anim
euthan
day
pi
gross
lung
patholog
evalu
necropsi
va
vad
unvaccin
control
calv
develop
lung
lesion
consist
previou
studi
bilater
multifoc
coalesc
area
pneumon
consolid
fig
c
howev
observ
prior
studi
vasbrsvnp
vaccin
anim
protect
sever
diseas
exhibit
signific
reduct
gross
lung
patholog
fig
c
surprisingli
howev
vadbrsvnp
vaccin
calv
protect
vaccin
develop
lung
lesion
similar
unvaccin
control
calv
fig
c
sampl
affect
unaffect
lung
tissu
anim
evalu
microscop
lesion
use
histopatholog
score
system
previous
lesion
consist
experiment
brsv
bronchointerstiti
pneumonia
necrot
bronchiol
seen
fig
vasbrsvnp
vaccin
calv
show
significantli
reduc
histolog
lesion
compar
vasunvaccin
calv
vadbrsvnp
vaccin
calv
differ
observ
vadunvaccin
vadbrsvnp
vaccin
calv
result
corrobor
prior
studi
show
singl
dose
intranas
brsvnp
vaccin
induc
partial
protect
brsv
infect
juvenil
calv
observ
benefit
inclus
solubl
fg
protein
brsvnp
vaccin
diseas
spare
va
vaccin
calv
similar
observ
prior
studi
brsvnp
vaccin
data
show
micronutri
statu
import
predictor
mucos
vaccin
efficaci
vad
calv
receiv
brsvnp
vaccin
show
protect
subsequ
brsv
challeng
nasal
swab
collect
anim
day
pi
detect
viral
shed
seen
fig
brsv
consist
detect
unvaccin
va
vad
control
day
infect
major
vadbrsvnp
vaccin
calv
howev
viru
detect
nasal
swab
less
vasbrsvnp
vaccin
calv
timepoint
challeng
lung
tissu
sampl
analyz
viral
burden
use
qpcr
detect
viral
gene
vasbrsvnp
vaccin
calv
significantli
reduc
lung
viral
burden
day
pi
compar
group
fig
consist
viru
isol
data
vadbrsvnp
vaccin
calv
high
titer
brsv
lung
show
reduct
lung
viral
burden
compar
unvaccin
vad
control
previous
shown
intranas
brsvnp
vaccin
prime
virusspecif
iga
product
upper
lower
respiratori
tract
virusspecif
cellular
immun
respons
airway
peripher
given
reduc
protect
observ
vad
vaccin
calv
next
examin
virusspecif
immun
respons
peripher
blood
respiratori
tract
brsv
f
g
protein
vasbrsvnp
vaccin
calv
mount
signific
iga
respons
brsv
f
g
protein
nasal
fluid
prior
brsv
challeng
result
consist
previou
studi
howev
day
follow
brsv
challeng
va
vaccin
calv
significantli
increas
concentr
virusspecif
iga
nasal
fluid
fig
bal
fig
compar
unvaccin
va
calv
virusspecif
iga
respons
respiratori
tract
includ
respons
f
g
protein
fig
contrast
va
cohort
vadbrsv
np
vaccin
anim
fail
mount
vaccineinduc
iga
respons
bal
nasal
fluid
fig
rumin
produc
signific
quantiti
mucos
surfac
therefor
also
analyz
brsvspecif
igg
isotyp
nasal
fluid
bal
fluid
day
infect
supplementari
fig
similar
iga
result
vasbrsv
np
vaccin
anim
increas
level
virusspecif
igg
bal
fluid
reduc
quantiti
virusspecif
igg
observ
nasal
secret
unvaccin
anim
va
vad
vadbrsv
np
vaccin
anim
quantiti
virusspecif
igg
nasal
fluid
significantli
differ
group
supplementari
fig
calv
studi
colostrum
replet
possess
preexist
brsvspecif
antibodi
titer
observ
differ
virusspecif
serum
igg
level
treatment
group
respons
vaccin
serum
neutral
titer
mean
rang
depict
group
tabl
cellular
immun
respons
evalu
lower
airway
peripher
blood
use
vitro
antigenrecal
assay
bal
mononuclear
cell
fig
b
pbmc
fig
isol
day
brsv
infect
restimul
vitro
describ
materi
method
cell
cultur
supernat
analyz
sandwich
elisa
left
panel
right
panel
bal
cell
pbmc
vasbrsvnp
vaccin
calv
secret
respons
brsv
restimul
respons
significantli
increas
vasunvaccin
control
vadbrsvnp
vaccin
anim
fig
bal
pbmc
sampl
also
collect
immedi
prior
challeng
evalu
vaccineinduc
cytokin
product
howev
similar
iga
result
detect
vaccineinduc
cellular
respons
either
airway
peripher
blood
prior
brsv
challeng
va
signific
impact
cell
innat
adapt
immun
system
particularli
gastrointestin
howev
less
understood
impact
vad
immun
system
respiratori
tract
particularli
context
acut
viral
infect
mous
model
pneumoviru
infect
vad
anim
present
hyperinflammatori
phenotyp
lung
elev
express
multipl
proinflammatori
investig
impact
vad
brsv
infect
lung
tissu
sampl
collect
unvaccin
brsv
infect
va
vad
calv
day
infect
analyz
qpcr
express
proinflammatori
cytokin
chemokin
seen
fig
express
significantli
higher
lung
vad
anim
compar
va
control
contrast
express
mucin
gene
significantli
reduc
vad
anim
compar
va
calv
express
significantli
differ
vad
va
anim
thu
vad
enact
profound
alter
immun
respons
acut
respiratori
infect
acut
ill
lead
sharp
decreas
circul
retinol
outcom
term
hyporetinemia
link
acut
phase
respons
rodent
challeng
endotoxin
retinol
transient
sequest
liver
tissu
reappear
plasma
shortli
appreci
irrevers
retinol
human
patient
howev
acut
ill
link
increas
va
observ
respiratori
infect
particular
implic
deplet
liver
va
store
howev
knowledg
studi
date
investig
impact
rsv
infect
va
level
nutritionallyreplet
infant
given
potenti
link
acut
infect
va
statu
close
examin
retinol
level
va
anim
undergo
acut
viral
infect
serum
sampl
collect
vasbrsvnp
vaccin
vasunvaccin
calv
day
post
infect
analyz
serum
retinol
seen
fig
consist
report
hyporetinemia
speci
serum
va
level
declin
vasunvaccin
calv
acut
brsv
infect
contrast
va
level
maintain
vasbrsvnp
immun
calv
undergo
significantli
reduc
clinic
diseas
fig
liver
va
level
va
calv
fig
analyz
base
vaccin
statu
observ
unvaccin
calv
reduc
liver
va
level
compar
vaccin
cohort
fig
fact
mean
liver
retinol
level
fell
accept
normal
rang
anim
render
va
defici
despit
va
replet
diet
also
analyz
liver
retinol
data
va
calv
base
brsvassoci
lung
patholog
score
seen
fig
liver
retinol
concentr
neg
correl
lung
patholog
indic
diseas
patholog
thu
acut
rsv
infect
signific
neg
impact
circul
store
retinol
level
even
vitaminreplet
individu
develop
efficaci
vaccin
rsv
challeng
due
natur
viru
also
target
popul
pose
signific
obstacl
rsv
infect
sever
prematur
infant
neonat
young
children
complic
rsv
infect
preval
develop
vad
endem
geograph
region
hit
hardest
also
signific
problem
prematur
infant
develop
develop
also
concern
vad
thought
diseas
develop
world
studi
suggest
subclin
vad
may
quit
critic
identifi
address
comorbid
host
factor
potenti
undermin
effect
vaccin
vad
target
popul
calf
model
brsv
infect
show
vad
profound
neg
impact
capac
host
respond
intranas
polyanhydrid
np
vaccin
resist
subsequ
viral
challeng
vad
calv
alter
inflammatori
cytokin
profil
lung
produc
virusspecif
iga
cellular
immun
respons
lung
peripher
blood
va
ra
play
defin
role
gut
immun
function
homeostasi
howev
result
emphas
va
also
play
import
role
immun
function
respiratori
tract
vad
calv
demonstr
heighten
inflammatori
cytokin
profil
lung
brsv
infect
increas
express
chemokin
result
consist
previou
report
penkert
et
al
mous
model
sendai
viru
sev
level
rant
increas
nasal
wash
vad
infect
anim
model
similar
vad
mice
fail
produc
virusspecif
iga
reduc
frequenc
cell
lung
follow
ra
promot
develop
regulatori
cell
inhibit
cell
dysregul
hyperinflammatori
phenotyp
observ
model
vad
attribut
defici
treg
howev
penkert
et
al
show
defect
treg
cell
differenti
sevinfect
given
reciproc
relationship
treg
cell
presenc
one
would
predict
increas
develop
increas
express
vad
system
thu
explain
alter
inflammatori
profil
howev
consist
find
lung
vad
calv
observ
significantli
reduc
express
similarli
detect
nasal
wash
vad
anim
sev
report
cha
et
al
vad
mice
significantli
reduc
express
reduc
number
cell
lamina
rudraraju
et
al
attribut
alter
inflammatori
profil
lung
sev
infect
mice
increas
viral
antigen
viral
persist
respiratori
tract
anim
sacrif
peak
infect
day
author
observ
differ
viral
titer
va
vad
howev
day
infect
va
anim
significantli
reduc
viral
load
compar
vad
author
specul
antigen
persist
defect
viral
clearanc
mechan
contribut
heighten
inflamm
lung
vad
anim
rather
defect
treg
skew
detect
differ
viru
shed
viral
load
vad
va
calv
day
infect
futur
studi
import
determin
vad
calv
display
similar
defect
viral
clearanc
later
stage
diseas
thu
explain
dysregul
cytokin
product
observ
lung
instead
defect
may
attribut
mechan
rsv
infect
imbal
axi
importantli
observ
signific
differ
express
lung
vad
calv
compar
va
control
suggest
treg
respons
may
intact
anim
howev
observ
increas
express
lung
vad
calv
express
play
regulatori
role
also
import
cytokin
elev
tissu
repair
contribut
lung
fibrosi
mucin
investig
impact
vad
respiratori
immun
system
respons
rsv
infect
warrant
nutritionist
long
recogn
acut
infect
exacerb
risk
malnutrit
measl
chickenpox
respiratori
infect
diarrhea
implic
deplet
liver
va
store
increas
risk
xerophthalmia
princip
clinic
manifest
va
howev
rel
studi
specif
address
impact
acut
respiratori
viral
infect
retinol
statu
vitamin
replet
individu
observ
serum
retinol
declin
cours
sever
brsv
infect
result
surpris
serum
va
regul
acut
phase
respons
vaadequ
rat
serum
retinol
declin
rapidli
follow
lp
challeng
return
normal
level
resolut
phase
minim
loss
retinol
urin
studi
radiolabel
retinol
reveal
major
retinol
redistribut
liver
tissu
infect
return
howev
contrari
report
consist
epidemiolog
data
human
data
suggest
acut
infect
caus
overal
loss
liver
store
studi
clear
retinol
store
consum
inflammatori
respons
excret
ill
howev
sever
impact
acut
viral
infect
va
store
caus
concern
potenti
fall
viciou
circl
acut
ill
defici
suscept
secondari
infect
va
supplement
obviou
solut
vad
current
recommend
largedos
oral
vitamin
supplement
immun
contact
va
supplement
signific
posit
impact
incid
howev
effect
diseas
less
clear
studi
report
signific
reduct
other
found
littl
effect
even
increas
incid
sever
diarrhea
respiratori
infect
children
receiv
vitamin
studi
specif
examin
impact
oral
va
supplement
rsv
infect
shown
one
studi
observ
increas
length
hospit
stay
infant
receiv
specul
oral
supplement
time
vaccin
may
ideal
address
vad
effect
respiratori
immun
respons
primarili
due
kinet
similar
principl
appli
supplement
acut
infect
chang
va
homeostasi
due
acut
inflamm
like
limit
va
access
inflam
tissu
prevent
modul
ongo
immun
respons
thu
futur
interest
investig
util
mucos
va
supplement
strategi
may
effici
approach
address
immunolog
lesion
observ
vad
individu
respiratori
vaccin
infect
previou
studi
shown
singl
dose
brsvnp
vaccin
afford
partial
protect
brsv
earli
studi
murin
model
inclus
solubl
protein
bolu
np
encapsul
antigen
use
boost
immunogen
np
therefor
current
studi
hypothes
administr
solubl
f
g
protein
suspens
np
encapsul
protein
would
enhanc
efficaci
compar
vaccineinduc
immun
respons
viral
burden
lung
patholog
studi
prior
observ
increas
immunogen
protect
mediat
modifi
approach
result
consist
recent
report
group
wherein
free
protein
compon
requir
polyanhydrid
nanovaccin
efficaci
mous
model
influenza
streptococcu
infect
futur
studi
heterolog
primeboost
approach
use
addit
rsv
target
protein
may
prove
efficaci
neonat
summari
confirm
prior
studi
show
singl
intranas
dose
brsvnp
vaccin
prime
protect
immun
neonat
calv
result
signific
reduct
virusassoci
clinic
diseas
lung
patholog
viral
lung
burden
follow
brsv
challeng
vad
enact
major
chang
lung
inflammatori
respons
brsv
infect
sever
neg
effect
immunogen
mucos
brsvnp
vaccin
show
acut
rsv
infect
potenti
induc
exacerb
vad
even
wellnourish
individu
indic
particular
care
taken
manag
nutrit
convalesc
infant
children
avoid
longterm
micronutri
defici
thu
suscept
secondari
infect
complic
sequala
recombin
fusion
f
protein
produc
genscript
piscataway
nj
use
recombin
baculoviru
express
system
previous
recombin
attach
g
protein
express
e
coli
previous
brsvfg
nanovaccin
prepar
previous
minor
modif
briefli
cpteg
cph
copolym
dissolv
methylen
chlorid
concentr
mgml
f
g
protein
suspend
solut
total
protein
concentr
mgml
mgml
protein
sonic
approxim
second
suspens
pour
pentan
volumetr
ratio
methylen
chlorid
pentan
suspens
vacuum
filter
collect
nanoparticl
nanoparticl
place
freezer
use
nanoparticl
yield
protein
encapsul
effici
ca
actual
protein
mass
encapsul
theoret
protein
mass
encapsul
anim
procedur
conduct
strict
accord
feder
institut
guidelin
approv
kansa
state
univers
institut
anim
care
use
committe
anim
care
protocol
includ
provis
human
endpoint
determin
discret
attend
clinic
veterinarian
method
minim
pain
distress
includ
avoid
prolong
restraint
inclus
euthanasia
intervent
strategi
total
fortythre
mixedgend
n
male
n
femal
holstein
calv
purchas
two
dairi
farm
one
southern
nebraska
n
one
central
ks
n
enrol
studi
birth
calv
randomli
assign
vad
va
treatment
group
calv
prevent
suckl
dam
instead
receiv
first
feed
colostrum
replac
within
h
birth
anim
receiv
g
fraction
colostrum
replac
milk
product
chilton
wi
reconstitut
l
water
approxim
colostrum
replac
contain
g
bovin
globulin
protein
concentr
colostr
whey
essenti
devoid
fatsolubl
vitamin
e
vitamin
iu
cholecalciferoldos
e
iu
alphatocopheraldos
ad
back
colostrum
replac
calv
va
iu
retinyl
palmit
ad
back
va
treatment
group
va
omit
colostrum
replac
vad
calv
anim
place
va
vad
milk
replac
diet
remaind
studi
milk
product
chilton
wi
calv
transport
larg
anim
research
center
kansa
state
univers
day
age
hous
group
calv
per
pen
pine
chip
bed
calv
bottlef
three
time
per
day
hour
apart
week
age
twice
per
day
hour
apart
milk
replac
consist
crude
protein
fat
fed
rate
lbsday
solid
va
calv
receiv
iu
va
retinyl
palmit
per
day
vad
anim
receiv
milk
replac
formul
without
va
calv
also
provid
ab
libitum
access
calf
starter
pellet
crude
protein
adf
start
week
age
starter
grain
formul
without
ad
va
vad
calv
iulb
va
calv
serum
retinol
level
monitor
weekli
sampl
submit
iowa
state
univers
veterinari
diagnost
laboratori
evalu
week
age
anim
divid
group
va
vaccin
n
femal
male
va
brsvnp
vaccin
n
male
femal
vad
vaccin
n
male
femal
vad
brsvnp
vaccin
n
male
femal
calv
vaccin
intranas
mg
brsvfg
load
cpteg
cph
nanoparticl
mg
recombin
f
g
protein
mg
solubl
recombin
f
g
protein
vaccin
suspend
ml
steril
salin
ml
deliv
nostril
calf
restrain
head
tilt
vaccin
administ
nose
use
syring
fit
nasal
cannula
equip
plastic
depth
control
ring
follow
vaccin
immun
respons
monitor
weekli
serum
peripher
blood
upper
nasal
fluid
collect
lower
bronchoalveolar
lavag
fluid
collect
respiratori
tract
six
calv
va
n
calv
male
vad
n
femal
male
sacrif
prior
challeng
sampl
lung
liver
tissu
collect
verifi
retinol
concentr
serv
control
tissu
immunolog
gene
express
studi
prechalleng
bronchoalveolar
lavag
bal
fluid
collect
anim
day
prior
brsv
infect
use
protocol
previous
modifi
stallion
cathet
blindli
pass
nose
advanc
trachea
lodg
bronchu
total
ml
steril
salin
divid
three
aliquot
aliquot
introduc
lower
respiratori
tract
follow
immedi
suction
obtain
lower
airway
wash
procedur
repeat
twice
three
aliquot
pool
end
procedur
bal
sampl
kept
ice
filter
steril
gauz
centrifug
x
g
minut
contamin
red
blood
cell
remov
use
hypoton
lysi
cell
wash
count
stimul
describ
antigen
recal
assay
brsv
strain
prepar
viru
stock
reisol
lung
infect
anim
passag
less
time
bovin
turbin
bt
cell
viral
inoculum
determin
free
bvdv
contamin
pcr
calv
inocul
via
aerosol
challeng
brsv
strain
previous
calv
monitor
twice
daili
clinic
ill
train
blind
observ
calv
score
use
adapt
univers
wisconsin
calf
health
respiratori
score
chart
origin
establish
dr
sheila
mcguirk
http
score
chart
assign
number
base
upon
fever
sever
clinic
sign
includ
cough
nasal
discharg
ocular
discharg
ear
posit
score
chart
includ
one
addit
categori
respiratori
effort
effort
signific
effort
nasal
swab
collect
calf
day
post
infect
place
viru
isol
media
serum
free
mem
antibiot
viru
isol
perform
previous
calv
euthan
day
postinfect
pi
barbitur
overdos
patholog
evalu
perform
similar
previou
extent
pneumon
consolid
evalu
use
score
system
postinfect
bal
fluid
collect
necropsi
remov
lung
trachea
introduc
ml
steril
icecold
salin
trachea
lung
massag
fluid
pour
back
trachea
steril
collect
bottl
sampl
affect
unaffect
lung
collect
multipl
site
histopatholog
evalu
tissu
fix
immers
neutral
buffer
formalin
process
routin
paraffinembed
section
section
stain
hematoxylin
eosin
microscop
lesion
evalu
pathologist
dr
henningson
blind
manner
sever
lung
lesion
score
base
upon
criteria
previous
peripher
blood
mononuclear
cell
pbmc
prepar
previous
cellsml
plate
roundbottom
plate
bronchoalveolar
lavag
fluid
bal
sampl
filter
steril
gauz
centrifug
minut
cellswel
resuspend
crpmi
plate
well
plate
pbmc
bal
cell
stimul
recombin
brsv
f
g
protein
moi
brsv
plate
incub
day
pbmc
hour
bal
cell
incub
cell
cultur
supernat
store
elisa
analysi
rna
isol
cdna
prepar
qpcr
perform
use
primer
sequenc
rel
gene
express
determin
use
refer
housekeep
gene
sampl
normal
uninfect
control
lung
tissu
collect
either
va
vad
calv
appropri
qpcr
perform
use
taqman
rnatoct
kit
appli
biosystem
viral
copi
number
calcul
use
standard
curv
lung
tissu
copi
number
normal
housekeep
gene
correct
differ
input
materi
qpcr
run
agil
realtim
pcr
machin
thermofish
scientif
quantstudio
realtim
pcr
machin
bovin
vetset
elisa
develop
kit
purchas
kingfish
biotech
inc
perform
accord
manufactur
instruct
indirect
elisa
use
quantifi
iga
igg
nasal
bal
fluid
elisa
plate
coat
overnight
f
g
protein
iga
brsv
stock
neg
control
well
coat
cell
cultur
media
prepar
uninfect
bt
cell
nasal
fluid
sampl
dilut
treat
mm
dithiothreitol
dtt
one
hour
prior
perform
elisa
bal
fluid
sampl
dilut
wash
buffer
sampl
plate
duplic
incub
h
room
temperatur
wash
mous
antibovin
igahrp
bethyl
laboratori
mous
antibovin
igghrp
use
plate
develop
use
pierc
ultra
tmp
substrat
thermoscientif
pierc
reaction
stop
addit
plate
read
optic
densiti
nm
nm
use
autom
plate
reader
baselin
prior
vaccin
prechalleng
day
serum
sampl
collect
submit
kansa
state
univers
veterinari
diagnost
laboratori
evalu
brsvspecif
viru
neutral
titer
statist
analysi
perform
use
prism
f
softwar
graphpad
softwar
inc
data
analyz
use
kruskalw
test
follow
dunn
multipl
comparison
test
student
ttest
correl
analysi
fig
perform
use
spearman
nonparametr
correl
test
